| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Department of Metabolism and Endocrinology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands
Address all correspondence and requests for reprints to: N. R. Biermasz, Department of Metabolism and Endocrinology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands. E-mail: nrbiermasz{at}lumc.nl.
Active acromegaly is associated with significant comorbidity and reduced quality of life. However, the prevalence of comorbidity after long-term remission is not established. Therefore, we assessed the presence of comorbidity in 118 patients in long-term remission after surgery, radiotherapy, and/or somatostatin analog treatment according to strict biochemical criteria of serum GH and IGF-I concentrations and evaluated the impact of comorbidity on quality of life. The mean duration of remission was 12.0 ± 7.4 yr, and mean actual IGF-I SD scores were 0.6 ± 1.7.
Self-reported joint problems occurred in 77% of patients, hypertension in 37%, a history of myocardial infarction in 9%, and diabetes mellitus in 11%. The presence of joint problems was not related to GH and IGF-I levels, active disease duration, or age. Joint complaints had significant negative impact on quality of life. Patients with a history of myocardial infarction had reduced scores for general health, depression, and fatigue, and diabetes mellitus was associated with reduced scores for anxiety and sleep.
In conclusion, acromegalic patients had a high prevalence of joint-related comorbidity and hypertension despite long-term control of GH excess. Especially, joint complaints contributed to a reduced perceived quality of life in these patients.
This article has been cited by other articles:
![]() |
N. R. Biermasz, M. J. E. Wassenaar, A. A. van der Klaauw, A. M. Pereira, J. W. A. Smit, F. Roelfsema, R. Wolterbeek, H. M. Kroon, M. Kloppenburg, and J. A. Romijn Pretreatment Insulin-Like Growth Factor-I Concentrations Predict Radiographic Osteoarthritis in Acromegalic Patients with Long-Term Cured Disease J. Clin. Endocrinol. Metab., July 1, 2009; 94(7): 2374 - 2379. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Wexler, L. Gunnell, Z. Omer, K. Kuhlthau, C. Beauregard, G. Graham, A. L. Utz, B. Biller, L. Nachtigall, J. Loeffler, et al. Growth Hormone Deficiency Is Associated with Decreased Quality of Life in Patients with Prior Acromegaly J. Clin. Endocrinol. Metab., July 1, 2009; 94(7): 2471 - 2477. [Abstract] [Full Text] [PDF] |
||||
![]() |
M J E Wassenaar, N R Biermasz, N van Duinen, A A van der Klaauw, A M Pereira, F Roelfsema, J W A Smit, H M Kroon, M Kloppenburg, and J A Romijn High prevalence of arthropathy, according to the definitions of radiological and clinical osteoarthritis, in patients with long-term cure of acromegaly: a case-control study Eur. J. Endocrinol., March 1, 2009; 160(3): 357 - 365. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. C. M. M. Neggers, M. O. van Aken, W. W. de Herder, R. A. Feelders, J. A. M. J. L. Janssen, X. Badia, S. M. Webb, and A. J. van der Lely Quality of Life in Acromegalic Patients during Long-Term Somatostatin Analog Treatment with and without Pegvisomant J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 3853 - 3859. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Miller, H. Doll, J. David, and J. Wass Impact of musculoskeletal disease on quality of life in long-standing acromegaly Eur. J. Endocrinol., May 1, 2008; 158(5): 587 - 593. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P Matta, E. Couture, L. Cazals, D. Vezzosi, A. Bennet, and P. Caron Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance Eur. J. Endocrinol., March 1, 2008; 158(3): 305 - 310. [Abstract] [Full Text] [PDF] |
||||
![]() |
B Havekes, A A van der Klaauw, H C Hoftijzer, J C Jansen, A G L van der Mey, A H J T Vriends, J W A Smit, J A Romijn, and E P M Corssmit Reduced quality of life in patients with head-and-neck paragangliomas Eur. J. Endocrinol., February 1, 2008; 158(2): 247 - 253. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. M. Dekkers, N. R. Biermasz, A. M. Pereira, J. A. Romijn, and J. P. Vandenbroucke Mortality in Acromegaly: A Metaanalysis J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 61 - 67. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. T'Sjoen, M. Bex, D. Maiter, B. Velkeniers, and R. Abs Health-related quality of life in acromegalic subjects: data from AcroBel, the Belgian Registry on acromegaly Eur. J. Endocrinol., October 1, 2007; 157(4): 411 - 417. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Georgitsi, A. Raitila, A. Karhu, K. Tuppurainen, M. J. Makinen, O. Vierimaa, R. Paschke, W. Saeger, R. B. van der Luijt, T. Sane, et al. Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations PNAS, March 6, 2007; 104(10): 4101 - 4105. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Melmed Acromegaly N. Engl. J. Med., December 14, 2006; 355(24): 2558 - 2573. [Full Text] [PDF] |
||||
![]() |
R. Kauppinen-Makelin, T. Sane, H. Sintonen, H. Markkanen, M. J. Valimaki, E. Loyttyniemi, L. Niskanen, A. Reunanen, U.-H. Stenman, and and the Finnish Acromegaly Study Group Quality of Life in Treated Patients with Acromegaly J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3891 - 3896. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |